Study guide
10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols
IJCAHPO Certified Retina Technician CRT
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview: Current CRT Requirements & Blueprint
Exam Overview: Current Requirements, Scope & Study Plan
2 Chapter 1: History Taking, Triage & Clinical Documentation
1.1 Comprehensive Ophthalmic & Medical History for Retina Patients 1.2 Telephone Triage, Urgent Symptoms & Emergency Scheduling 1.3 Scribing, Electronic Health Records & Retinal Billing Codes
3 Chapter 2: Visual Assessment & Low Vision Rehabilitation
2.1 Standardized Visual Acuity Testing & Optotypes 2.2 Sub-Chart Acuity Protocols: CF, HM, LP, and NLP 2.3 Low Vision Definitions, Optical Devices & Patient Counseling
4 Chapter 3: Pupil Assessment & Visual Field Testing
3.1 Pupillary Examination & Relative Afferent Pupillary Defect 3.2 Confrontation Fields & Automated Perimetry in Retina 3.3 Amsler Grid Testing & Metamorphopsia Monitoring
5 Chapter 4: Tonometry & Ocular Motility
4.1 Goldmann Applanation & Handheld Tonometry Techniques 4.2 Tonometer Disinfection, Calibration & Post-Procedure IOP Monitoring 4.3 Ocular Motility Assessment, Strabismus & Alignment Testing
6 Chapter 5: Diagnostic Ophthalmic Ultrasound
5.1 Ophthalmic B-Scan Echography for Posterior Segment Pathology 5.2 Standardized A-Scan Echography & Optical Biometry
7 Chapter 6: Slit Lamp, Electrophysiology & Supplemental Testing
6.1 Slit Lamp Biomicroscopy, Illumination & Fundus Lenses 6.2 Color Vision Assessment & Hertel Exophthalmometry 6.3 Ophthalmic Electrophysiology: ERG, VEP, and EOG
8 Chapter 7: Ophthalmic Microbiology & Infection Control
7.1 Ocular Pathogens & Routes of Disease Transmission 7.2 Clinical Asepsis, Universal Precautions & Vitreous Specimen Collection
9 Chapter 8: General Retinal Pharmacology & Therapeutics
8.1 Ocular Drug Delivery Methods & Routes of Administration 8.2 Mydriatics, Cycloplegics & Diagnostic Ophthalmic Dyes 8.3 Anesthetics, Glaucoma Agents & Prescription Verification
10 Chapter 9: Anti-VEGF Therapies, Steroids & Retinal Toxicity
9.1 Anti-VEGF Agents & Neovascular Retinal Diseases 9.2 Corticosteroids, Sustained-Release Implants & AREDS Supplements 9.3 Systemic Medication Retinal Toxicity & Plaquenil Screening
11 Chapter 10: Surgical Assisting & Intravitreal Procedures
10.1 Intravitreal Injection Protocol, Antisepsis & Complication Checks 10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols 10.3 Surgical Instrument Handling, Tray Setup & Sterilization
12 Chapter 11: Patient Services, Education & Clinical Care
11.1 Patient Education, Chronic Disease Counseling & Treatment Adherence 11.2 Special Needs Accommodations, Patient Diversity & Interpersonal Skills 11.3 Ophthalmic Emergencies, First Aid & Clinical Care Coordination 11.4 Clinic Operations, Research Support, Forms & Referrals
13 Chapter 12: General Ocular Anatomy & Retinal Physiology
12.1 Ocular Anatomy, Orbit & Posterior Segment Architecture 12.2 Ten Retinal Layers, Photoreceptors & Macular Anatomy 12.3 Ocular Blood Supply, Microcirculation & Vitreoretinal Interface 12.4 Body Systems, Ocular Adnexa & Medical Terminology
14 Chapter 13: Retinal Pathology & Systemic Disease Manifestations
13.1 Age-Related Macular Degeneration & Retinal Vascular Occlusions 13.2 Diabetic Retinopathy & Systemic Diseases Affecting the Retina 13.3 Peripheral Retinal Degenerations, Tears & Detachments
15 Chapter 14: Ophthalmic Optics & Lensometry
14.1 Principles of Ophthalmic Optics & Refraction 14.2 Manual & Automated Lensometry Techniques
16 Chapter 15: Fundus Photography & Ophthalmic Angiography
15.1 Fundus Photography Techniques & Fundus Autofluorescence 15.2 Fluorescein Angiography Principles, Phases & Image Interpretation 15.3 Indocyanine Green Angiography & Angiographic Complication Management
17 Chapter 16: Optical Coherence Tomography (OCT & OCT-A)
16.1 OCT Principles, Scan Acquisition & Artifact Recognition 16.2 Structural OCT Interpretation: Retinal Fluid & Biomarkers 16.3 Optical Coherence Tomography Angiography (OCT-A) Principles & Flow
18 Chapter 17: Equipment Maintenance, Ethics & Regulatory Compliance
17.1 Equipment Maintenance, Calibration Schedules & Clinic Safety 17.2 Medical Ethics, Scope of Practice & Informed Consent 17.3 Patient Privacy, HIPAA Standards & Hazardous Waste Disposal
10.2 Retinal Laser Therapy Modalities & Laser Safety Protocols
Key Takeaways Explain This Topic AI
Laser eyewear is selected from the laser safety officer's wavelength, maximum permissible exposure, and optical-density analysis, not from a memorized universal OD value.
The time-out confirms patient, eye, treatment plan, wavelength, delivery system, contact lens, and team readiness before the laser is enabled.
PRP reduces ischemic drive and the risk of severe vision loss in selected proliferative disease but can affect peripheral field, night vision, and macular edema.
The current U.S. VISUDYNE label calls for protection from direct sunlight and bright indoor light for five days, not 48 hours, and says ordinary indoor light supports photobleaching.
Unexpected pain, smoke, equipment warning, fire risk, wrong-site concern, or patient movement is a stop event.
Last updated: September 2026
Retinal Laser Therapy and Laser Safety
Retinal laser systems can deliver enough optical energy to injure retina, cornea, skin, or staff eyes. Safe assisting combines clinical verification with a formal laser-safety program. The technician does not choose treatment spots, power, duration, or endpoint unless a lawful, delegated protocol explicitly assigns a technical control.
Common treatment concepts
Panretinal photocoagulation (PRP) places burns in peripheral ischemic retina to reduce angiogenic drive in selected proliferative retinopathies. Focal or grid treatment may target defined leakage patterns in selected conditions. Retinopexy creates chorioretinal adhesion around a break. Photodynamic therapy (PDT) activates verteporfin with a specified nonthermal wavelength in selected choroidal disorders.
Each procedure has different indications, optics, contact lenses, parameters, and risks. Do not describe every laser as sealing a leak or directly destroying new vessels. The clinician selects treatment from the diagnosis and current evidence.
Controlled-area preparation
Before use:
verify service and self-test status, key control, emergency stop, footswitch, delivery fiber, slit-lamp coupling, filters, and warning light;
- restrict access and display the required warning sign;
- remove reflective jewelry or instruments when relevant and manage flammable material;
- provide wavelength-specific eyewear for everyone who requires it;
- confirm smoke evacuation or plume control when the procedure generates plume;
prepare the correct contact lens, coupling agent, and sterile supplies.
Protective eyewear is not selected by color or a generic OD 5 label. The laser safety officer or approved chart determines the wavelength range and optical density from the system output and exposure analysis. Eyewear for a 532 nm laser may not protect against an 810 nm system.
Time-out and treatment support
Use two identifiers and confirm the eye, planned procedure, laser, wavelength, delivery system, consent status, and treatment plan. Position the patient and explain fixation without promising a painless or complication-free procedure. Maintain stable contact-lens coupling and promptly report loss of view, corneal drying, patient movement, equipment alarms, or an unexpected tissue effect.
Only the treating clinician changes power, spot size, duration, pattern, or endpoint unless the documented delegation and policy state otherwise. Record the parameters reported by the laser system and practitioner; do not reconstruct them from memory.
Laser hazards
Direct, reflected, or scattered radiation can injure tissue. The risk depends on wavelength, power, pulse duration, beam geometry, distance, and exposure. Nonbeam hazards include electrical energy, fire, compressed gas, trip hazards, plume, and medication reactions. Keep the emergency stop accessible and never bypass an interlock or warning.
If a wrong-eye concern, unexpected burn, smoke, fire, eyewear failure, or system fault occurs, stop delivery, keep the patient safe, and notify the responsible clinician and laser safety officer.
Verteporfin counseling
The current U.S. VISUDYNE prescribing information warns that patients are photosensitive after infusion. For five days , they should avoid direct sunlight and bright indoor light such as tanning salons, bright halogen lighting, and high-power surgical or dental lights. If daylight exposure is unavoidable, protect skin and eyes with clothing and dark sunglasses; ultraviolet sunscreen alone is not sufficient because visible light can activate residual drug.
Patients should not remain in darkness. Ordinary indoor ambient light helps photobleach the drug. Prolonged exposure to light-emitting medical devices on the skin should also be avoided during the labeled interval. Give the current manufacturer handout because labeling can change.
Post-procedure documentation
Record patient, eye, laser and wavelength, lens, delivered settings and counts as reported, personnel, complications, and instructions. Reinforce clinician-approved warning signs and follow-up. PRP may reduce peripheral field or night vision and may worsen macular edema; retinopexy does not guarantee that detachment cannot occur. New symptoms are escalated promptly.
The exam principle is that laser safety is engineered and wavelength-specific, while treatment decisions remain clinician-directed.
Room control and post-procedure handoff
Control entry while the laser is enabled, display the required warning, minimize reflective items, and keep the key or enable control with authorized staff. Confirm that the delivery lens, filters, microscope, fiber, foot pedal, plume control when applicable, and emergency stop match the system. Everyone in the nominal hazard zone uses protection selected for the operating wavelength and exposure; ordinary sunglasses and generic "laser glasses" are not substitutes.
Record the device, wavelength, treated eye, operator, delivered settings and counts as required, protective measures, complications, and any aborted portion. The clinician supplies the diagnosis and treatment interpretation. After photodynamic therapy with verteporfin, give the current product-specific light precautions exactly as written and confirm understanding; do not shorten the labeled interval from memory. Route severe pain, sudden vision change, neurologic symptoms, or an equipment-related event through the emergency and incident-reporting processes.